Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study

Predicting Factors of Plasma HIV RNA Undetectability after Switching to Co-Formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Experienced HIV-1 Patients: A Multicenter Study

Switching to bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) from other antiretroviral regimens is safe and effective for virologically suppressed people living with HIV (PLWH). The term virological suppression includes both low but detectable HIV viremia and undetectable HIV vir...

Full description

Bibliographic Details
Main Authors:	Monica Basso, Giuliana Battagin, Stefano Nicolè, Maria Cristina Rossi, Francesco Colombo, Nicole Pirola, Stefano Baratti, Silvia Storato, Federico Giovagnorio, Vincenzo Malagnino, Grazia Alessio, Antonio Vinci, Massimo Maurici, Loredana Sarmati, Saverio Giuseppe Parisi
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Viruses
Subjects:	co-formulated bictegravir emtricitabine and tenofovir alafenamide experienced HIV-1-positive patients HIV RNA undetectability HIV RNA control prior to switch CD4+ nadir
Online Access:	https://www.mdpi.com/1999-4915/15/8/1727

Similar Items

Clinical efficacy, safety, and subjective experience based on ePRO in HIV‐infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China
by: Linghong Kong, et al.
Published: (2023-08-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?
by: Januszka JE, et al.
Published: (2023-11-01)

Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)
by: Anna Gidari, et al.
Published: (2023-12-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-07-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
by: Canetti D, et al.
Published: (2023-12-01)

Assessment of Gastrointestinal Adverse Effects during the First Six Months of “Biktarvy” Antiretroviral Therapy: Age-Related Patterns and Their Relation with Changes of 5 kg Weight Loss/Gain in the Initial Treatment Period
by: Madalina-Ianca Suba, et al.
Published: (2023-12-01)

Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV
by: Giuseppe Vittorio De Socio, et al.
Published: (2023-12-01)

Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice
by: Daniele Armenia, et al.
Published: (2022-09-01)

An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
by: Lee A. Evitt, et al.
Published: (2023-03-01)

Increased human immunodeficiency virus viral load with cerebral infarction due to varicella zoster virus vasculopathy on treatment with bictegravir/emtricitabine/tenofovir alafenamide suspension: a case report and literature review
by: Kazuhiro Ishikawa, et al.
Published: (2023-07-01)

Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort
by: Alessandro Lazzaro, et al.
Published: (2023-05-01)

Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV
by: Baptiste Sellem, et al.
Published: (2023-03-01)

Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study
by: Thomas C.S. Martin, et al.
Published: (2020-11-01)

A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model
by: Haneesha Mohan, et al.
Published: (2022-08-01)

Bictegravir and Metformin Drug-Drug Interaction in People with Human Immunodeficiency Virus (HIV)
by: Anne M. Masich, et al.
Published: (2023-04-01)

Switching to a Bictegravir Single Tablet Regimen in Elderly People Living with HIV-1: Data Analysis from the BICTEL Cohort
by: Alessandro Lazzaro, et al.
Published: (2021-12-01)

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study
by: Bruce Rashbaum, et al.
Published: (2019-01-01)

Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023)
by: Enos Moyo, et al.
Published: (2022-10-01)

eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort
by: Ramón Teira, et al.
Published: (2021-09-01)

Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations
by: Paul Curley, et al.
Published: (2023-06-01)

Raltegravir, tenofovir, and emtricitabine in an HIV-Infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver Toxicity
by: Ortu F, et al.
Published: (2010-02-01)

Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling
by: Tom G. Jacobs, et al.
Published: (2023-05-01)

Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
by: Rachel K. Scott, et al.
Published: (2023-09-01)

Pre-exposure prophylaxis (PrEP) efficacy to reduce HIV/AIDS incidence rate among male sex to male (MSM) in Asia
by: Prayogi Miura-Susanto
Published: (2023-01-01)

A Comparison between the Efficiency of Vonavir (Tenofovir-Emtricitabine- Efavirenz) and Cobavir (Lamivudine-Zidovudine) with Efavirenz used for HIV Patients in Fasa, Iran
by: Saeideh Honarmand, et al.
Published: (2022-07-01)

Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis
by: Keith Dunn, et al.
Published: (2021-07-01)

Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide
by: Ling-Ya Chen, et al.
Published: (2023-06-01)

Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study
by: Javier Perez Stachowski, et al.
Published: (2022-08-01)

Humoral Response after Two Doses of BNT162b2 mRNA Vaccine Has a Role in Predicting Response after Three Doses That Is Related to Plasma HIV Viremia and Nadir CD4+ Cell Count in HIV-Positive Patients
by: Monica Basso, et al.
Published: (2022-12-01)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir Plus Lamivudine for Switch Therapy in Patients with HIV-1 Infection: A Real-World Cohort Study
by: Lin Gan, et al.
Published: (2023-10-01)

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
by: Alexa Vyain Zhao, et al.
Published: (2022-10-01)

A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir
by: Andrea R. Thurman, et al.
Published: (2023-04-01)

A possible case of bictegravir-associated severe unconjugated hyperbilirubinemia
by: Kanak Parmar, et al.
Published: (2023-01-01)

The Association of HIV-1 Neutralization in Aviremic Children and Adults with Time to ART Initiation and CD4+/CD8+ Ratios
by: Victor Sanchez-Merino, et al.
Published: (2023-12-01)

Pathogenesis of HIV Infection
by: İftihar KÖKSAL
Published: (1997-06-01)

Renal function and lipid metabolism in Japanese HIV-1-positive individuals 288 weeks after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate: a single-center, retrospective cohort study
by: Kensuke Abe, et al.
Published: (2024-02-01)

A Mathematical Model for HIV/AIDS Under Pre-Exposure and Post-Exposure Prophylaxis
by: Erick Manuel Delgado Moya, et al.
Published: (2022-10-01)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
by: Inès Devred, et al.
Published: (2023-09-01)

Comparison of the Effects of Three Dual-Nucleos(t)ide Reverse Transcriptase Inhibitor Backbones on Placenta Mitochondria Toxicity and Oxidative Stress Using a Mouse Pregnancy Model
by: Kayode Balogun, et al.
Published: (2022-05-01)

Analysis of HIV RNA Results in HIV/AIDS Patients
by: Kadriye Kart Yaşar, et al.
Published: (2014-06-01)